A biotech company dedicated to transforming healthcare through innovative gene therapies. Our mission is to extend healthy lifespans and create a future where aging is synonymous with vitality.
Our Vision: To revolutionize healthcare by providing accessible and effective gene therapies that address a wide range of diseases.
Our Approach: Infirmacea's innovative fat-directed DNA therapy involves injecting DNA into subcutaneous fat, transforming it into a "health engine", promoting disease resistance. Since fat is abundant and easily accessible by injection, it serves as an ideal target for gene therapy, making this approach both efficient and practical.
Key Technologies:
1. Human Fat Culture System (exFat): A proprietary platform that enables to discover “real human” outcome by interventions.
2. Gene Expression Enhancer (gBoost): A revolutionary technology for boosting cell-selective gene expression regardless of delivery systems (viral or non-viral).
Product development:
1. Initial Focus: Obesity and Muscle Loss
2. Market Opportunity: Capitalizing on the rapidly growing anti-obesity market, driven by the success of GLP-1 drugs like Ozempic, Wegovy, and Zepbound.
3. Product Development: Developing a gene therapy product to address muscle loss, a common drawback of GLP-1 therapies.
4. Strategic Approach: Initially focusing on combination therapy with GLP-1 drugs to expedite market entry and subsequently exploring standalone therapy.
Current focus: Seeking for gBoost licensing opportunities to gene therapy companies, particularly those working with adeno-associated virus (AAV)
Future Directions: Expanding Indications: Identifying additional target genes for age-related muscle loss, using human fat samples from various age groups.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Chiba City, Jp
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.infirmacea.com
- Keywords
- DNA therapy, gene therapy, gene delivery, fat-directed DNA therapy, plasmid, obesity, anti-aging, safe and affordable gene therapy, tissue culture, transcriptome analysis, aging analysis, gBoost, exFat, tech licensing.
- HQ
- Chiba City
Infirmacea Inc. Questions
Infirmacea Inc.'s website is https://www.infirmacea.com
Infirmacea Inc.'s LinkedIn profile is https://jp.linkedin.com/company/infirmacea
Infirmacea Inc. has
1 employees.
View email and phone details for 1
employees at Infirmacea Inc..
Infirmacea Inc.'s industry is
Biotechnology Research
Infirmacea Inc.'s top competitors are
Trioxnano - Programmed Medicine,
Generatixe, Inc.,
I-Dna Biotechnology Pte Ltd,
Genisphere,
Nvigen Inc.,
Skin Life Analytics,
Hera Biolabs,
Couragene,
Soft Transport Biosystem Inc.,
Entwine Bio.
Infirmacea Inc.'s categories are Biotechnology Research
Infirmacea Inc.'s founding year is 2021
